Gefitinib improves severe bronchorrhea and prolongs the survival of a patient with lung invasive mucinous adenocarcinoma:A case report  

作　　者：Guo-Chun Ou Wen Luo Wei-Shan Zhang Shu-Hong Wang Jie Zhao Hong-Mei Zhao Rong Qiu 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Suining Central Hospital,Suining 629000,Sichuan Province,China [2]Department of Pathology,Suining Central Hospital,Suining 629000,Sichuan Province,China

出　　处：《World Journal of Clinical Cases》2023年第2期441-448,共8页世界临床病例杂志

基　　金：Supported by the Science and Technology Research Project of Sichuan Provincial Administration of Traditional Chinese Medicine,No.2021MS164;Scientific research project of Sichuan Medical Association,No.S21012。

摘　　要：BACKGROUND Lung invasive mucinous adenocarcinoma(LIMA),formerly referred to as mucinous bronchioloalveolar carcinoma,is a rare disease that usually presents as bilateral lung infiltration,is unsuitable for surgery and radiotherapy,and shows poor response to conventional chemotherapy.CASE SUMMARY We report a 56-year-old Chinese man with a history of smoking and epidermal growth factor receptor mutation-positivity who was initially misdiagnosed as severe pneumonia,but was ultimately diagnosed as a case of invasive mucinous adenocarcinoma of the lung by computed tomography-guided percutaneous lung biopsy.Bronchorrhea and dyspnea were improved within 24 h after initiation of gefitinib therapy and the radiographic signs of bilateral lung consolidation showed visible improvement within 30 d.After more than 11 months of treatment,there is no evidence of recurrence or severe adverse events.CONCLUSION Although the precise mechanism of the antitumor effects of gefitinib are not clear,our experience indicates an important role of the drug in LIMA and provides a reference for the diagnosis and treatment of this disease.

关 键 词：GEFITINIB Epidermal growth factor receptor Lung cancer Bronchorrhea Lung invasive mucinous adenocarcinoma Case report 

分 类 号：R734.2[医药卫生—肿瘤]